Five Top Papers From 2014 That Will Impact Your Practice
New drugs that treat stubborn illness seen often in primary care lead this group of Top 5 Papers for 2014. Type 2 diabetes, cryptogenic stroke, and hep-C are key targets.
SGLT2 Inhibitors: Pros, Cons, Comparisons, and Considerations
There are 2 FDA-approved sodium-glucose contransporter-2 inhibitors available in the United States. Here, a concise review of advantages/disadvantages and considerations in patient selection.
By clicking Accept, you agree to become a member of the UBM Medica Community.